Glaucoma

Sinha, Sapna; Shalaby, Wesam Shamseldin; Liu, Wendy W.; Razeghinejad, Reza; Katz, L. Jay

doi:10.1016/b978-0-12-820472-6.00117-1

Cited by 1 publication

(1 citation statement)

References 347 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it has a sulphonamide moiety, this is not cross-reactive, so does not need to be avoided by people who are allergic to sulfonamide antibiotics such as sulfamethoxazole. 33,34 A 2016 phase III trial by Tanihara et al 12 examined the safety of ripasudil 0.4% when applied twice daily over a 52 week period and found the most frequent adverse drug reactions (ADRs) to be conjunctival hyperaemia (n = 264, 74.6%), blepharitis (n = 73, 20.6%), allergic conjunctivitis (n = 61, 17.2%), eye irritation (n = 36, 10.2%), conjunctivitis (n = 26, 7.3%) and eyelids pruritus (n = 16, 4.5%), where patients can have a combination of ADRs. This represented a high overall rate of ADRs at 85.0%, which reduced to 18.6% in the reporting of 12-month post-marketing surveillance (PMS).…”

Section: Safety Profile Of Ripasudilmentioning

confidence: 99%

ROCK inhibitors in ophthalmology: A critical review of the existing clinical evidence

Karri

Chong

2023

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Rho kinase (ROCK) inhibitors have emerged as a key therapeutic class of interest in ophthalmology over the last decade. Promising in vitro studies laid the foundations for the development of novel therapeutic agents that target the ROCK signalling pathway in ocular disease, with subsequent clinical trials supporting their use. Corneal endothelial disease, glaucoma, and vitreoretinal disease are the major pathologies in which ROCK inhibitors have been investigated to date. Ripasudil and netarsudil represent the current leaders in this pharmaceutical group, having been extensively validated and approved for use in glaucoma in some countries. Less substantial evidence exists for fasudil in ophthalmic use. ROCK inhibitors are also increasingly used in cultured endothelial cell grafting and as an adjunct to aid in endothelial cell migration and replication in Descemet's stripping procedures or Descemet's membrane injuries. This review has synthesised both established and emerging research to provide a practical guide to prescribing in this drug class. Drug efficacies, side effect profiles, and the demographic and clinical characteristics of appropriate drug candidates are discussed.

show abstract

Section: Safety Profile Of Ripasudilmentioning

confidence: 99%